Numerix: The True Cost of OTC Derivatives Funding - FVA, OIS and Profitability

The question at the root of the OTC derivatives decision process, “Is this trade profitable?”, may at its core seem like a simple proposition. But in the changing world of OTC derivatives, this culmination of calculations has become increasingly complex, especially from a funding perspective.

In this video blog, Tom Davis, PhD, VP of Client Services and Product Manager of CrossAsset, joins Jim Jockle, CMO, to explore the connection between funding and profitability.

Through this discussion

Only users who have a paid subscription or are part of a corporate subscription are able to print or copy content.

To access these options, along with all other subscription benefits, please contact [email protected] or view our subscription options here:

You are currently unable to copy this content. Please contact [email protected] to find out more.

To continue reading...

You need to sign in to use this feature. If you don’t have a RiskTech Forum account, please register for a trial.

Sign in
You are currently on corporate access.

To use this feature you will need an individual account. If you have one already please sign in.

Sign in.

Alternatively you can request an individual account here: